Myocardial interstitial fibrosis in heart failure: biological and translational perspectives
Myocardial interstitial fibrosis contributes to left ventricular dysfunction leading to the
development of heart failure. Basic research has provided abundant evidence for the …
development of heart failure. Basic research has provided abundant evidence for the …
Cellular and engineered organoids for cardiovascular models
An ensemble of in vitro cardiac tissue models has been developed over the past several
decades to aid our understanding of complex cardiovascular disorders using a reductionist …
decades to aid our understanding of complex cardiovascular disorders using a reductionist …
Generation of human iPSCs derived heart organoids structurally and functionally similar to heart
SG Lee, YJ Kim, MY Son, MS Oh, J Kim, B Ryu… - Biomaterials, 2022 - Elsevier
Currently, due to the increasing demand for 3D culture, various organoids that mimic organs
are being actively studied. Despite active reports, information on heart organoids (HOs) …
are being actively studied. Despite active reports, information on heart organoids (HOs) …
CRISPR modeling and correction of cardiovascular disease
Cardiovascular disease remains the leading cause of morbidity and mortality in the
developed world. In recent decades, extraordinary effort has been devoted to defining the …
developed world. In recent decades, extraordinary effort has been devoted to defining the …
Patient and disease–specific induced pluripotent stem cells for discovery of personalized cardiovascular drugs and therapeutics
Human induced pluripotent stem cells (iPSCs) have emerged as an effective platform for
regenerative therapy, disease modeling, and drug discovery. iPSCs allow for the production …
regenerative therapy, disease modeling, and drug discovery. iPSCs allow for the production …
[HTML][HTML] Long QT syndrome: genetics and future perspective
Long QT syndrome (LQTS) is an inherited primary arrhythmia syndrome that may present
with malignant arrhythmia and, rarely, risk of sudden death. The clinical symptoms include …
with malignant arrhythmia and, rarely, risk of sudden death. The clinical symptoms include …
Use of human induced pluripotent stem cell–derived cardiomyocytes in preclinical cancer drug cardiotoxicity testing: a scientific statement from the American Heart …
It is now well recognized that many lifesaving oncology drugs may adversely affect the heart
and cardiovascular system, including causing irreversible cardiac injury that can result in …
and cardiovascular system, including causing irreversible cardiac injury that can result in …
Use of human induced pluripotent stem cell–derived cardiomyocytes to assess drug cardiotoxicity
Cardiotoxicity has historically been a major cause of drug removal from the pharmaceutical
market. Several chemotherapeutic compounds have been noted for their propensities to …
market. Several chemotherapeutic compounds have been noted for their propensities to …
A computational model of induced pluripotent stem‐cell derived cardiomyocytes incorporating experimental variability from multiple data sources
Key points Induced pluripotent stem cell‐derived cardiomyocytes (iPSC‐CMs) capture
patient‐specific genotype–phenotype relationships, as well as cell‐to‐cell variability of …
patient‐specific genotype–phenotype relationships, as well as cell‐to‐cell variability of …
A premature termination codon mutation in MYBPC3 causes hypertrophic cardiomyopathy via chronic activation of nonsense-mediated decay
Background: Hypertrophic cardiomyopathy (HCM) is frequently caused by mutations in
myosin-binding protein C3 (MYBPC3) resulting in a premature termination codon (PTC). The …
myosin-binding protein C3 (MYBPC3) resulting in a premature termination codon (PTC). The …